Agrusa Jennifer E, Scull Brooks P, Abhyankar Harshal A, Lin Howard, Ozuah Nmazuo W, Chakraborty Rikhia, Eckstein Olive S, Gulati Nitya, Fattah Elmoataz Abdel, El-Mallawany Nader K, Rouce Rayne H, Dreyer ZoAnn E, Brackett Julienne, Margolin Judith F, Lubega Joseph, Horton Terzah M, Bollard Catherine M, Gramatges M Monica, Kamdar Kala Y, McClain Kenneth L, Man Tsz-Kwong, Allen Carl E
Department of Pediatrics, Baylor College of Medicine, Texas Children's Cancer and Hematology Centers, Houston, TX 77030, USA.
Center for Cancer and Immunology Research, Children's National Health System and The George Washington University, Washington, DC 20010, USA.
Cancers (Basel). 2020 Dec 2;12(12):3603. doi: 10.3390/cancers12123603.
Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed-Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of inflammatory cytokines or chemokines in pre-therapy plasma of children with HL. The study objectives were to better define the inflammatory pre-therapy plasma proteome and identify plasma biomarkers associated with extent of disease and clinical outcomes in pediatric HL. Pre-therapy plasma samples were obtained from pediatric subjects with newly diagnosed HL and healthy pediatric controls. Plasma concentrations of 135 cytokines/chemokines were measured with the Luminex platform. Associations between protein concentration and disease characteristics were determined using multivariate permutation tests with false discovery control. Fifty-six subjects with HL (mean age: 13 years, range 3-18) and 47 controls were analyzed. The cytokine/chemokine profiles of subjects with HL were distinct from controls, and unique cytokines/chemokines were associated with high-risk disease (IL-10, TNF-α, IFN-γ, IL-8) and slow early response (CCL13, IFN-λ1, IL-8). TNFSF10 was significantly elevated among those who ultimately relapsed and was significantly associated with worse event-free survival. These biomarkers could be incorporated into biologically based risk stratification to optimize outcomes and minimize toxicities in pediatric HL.
霍奇金淋巴瘤(HL)的组织病理学特征是在炎症浸润中存在罕见的恶性里德-施特恩伯格细胞。我们推测,儿童HL病变中的炎症特征可通过HL患儿治疗前血浆中炎症细胞因子或趋化因子的水平反映出来。本研究的目的是更好地界定治疗前炎症血浆蛋白质组,并确定与儿童HL疾病范围和临床结局相关的血浆生物标志物。从新诊断为HL的儿科受试者和健康儿科对照中获取治疗前血浆样本。使用Luminex平台测量135种细胞因子/趋化因子的血浆浓度。采用具有错误发现控制的多变量排列检验确定蛋白质浓度与疾病特征之间的关联。对56例HL受试者(平均年龄:13岁,范围3 - 至18岁)和47例对照进行了分析。HL受试者的细胞因子/趋化因子谱与对照不同,并且独特的细胞因子/趋化因子与高危疾病(IL - 10、TNF -α、IFN -γ、IL - 8)和早期反应缓慢(CCL13、IFN -λ1、IL - 8)相关。TNFSF10在最终复发的患者中显著升高,并且与无事件生存期较差显著相关。这些生物标志物可纳入基于生物学的风险分层,以优化儿童HL的治疗结局并将毒性降至最低。